Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan

Partnership aims to include Aclarion’s surgical decision support technology within ATEC’s AlphaInformatiX platform to better inform spine surgery

Aclarion’s Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine to help physicians identify the location of chronic low back pain

BROOMFIELD, CO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it has executed a strategic partnership agreement solidifying the previously signed non-binding Letter of Intent (“LOI”) with Alphatec Spine, Inc., the wholly owned operating subsidiary of Alphatec Holdings, Inc. (Nasdaq: ATEC).

Uniting the unique structural information powered by ATEC’s AlphaInformatiX platform with the innovative biomarker data that enables Aclarion’s Nociscan solution to help identify potentially painful discs will provide surgeons with unprecedented data on one platform. That platform will be designed to improve clinical outcomes, while reducing overall procedural costs for patients with chronic low back pain (cLBP).

The agreement memorializes a multi-step strategic partnership in which ATEC and Aclarion have committed to work together to identify key opinion leader (KOL) surgeons to evaluate the Nociscan technology. Feedback from the surgeons will inform clinical evaluations designed to assess the utility of Nociscan in conjunction with EOS imaging, the foundation of ATEC’s AlphaInformatiX platform. As positive synergies emerge, ATEC and Aclarion intend to co-market Nociscan in targeted markets. In exchange for select access to ATEC’s surgeon network for the evaluation and advancement of Nociscan, Aclarion has agreed to provide ATEC with certain exclusive distribution rights to include Nociscan as part of an integrated procedural solution.

Pat Miles, Chairman and CEO of ATEC, commented, “Moving from our previously signed LOI to this agreement in just a matter of weeks demonstrates our shared vision for the solution we can create together. We share an intent to move through the phases of the agreement efficiently and have already identified internal leaders and resources to accomplish the first phase in the weeks to come. We believe in the importance of biochemical markers within the treatment paradigm and by partnering with Aclarion, we can progress toward a mutual objective to integrate and advance technologies that improve the predictability and reproducibility of spine patient care.”